Objective: Resective therapeutic strategy for left-sided pancreatic adenocarcinoma is open to debate. The post-resection outcomes and factors influencing post-resection survival for adenocarcinoma of the body and tail of the pancreas were analyzed to determine the effectiveness of surgery. Methods: A total of 73 patients with adenocarcinoma of the body or tail of the pancreas who underwent resection between 1994 and June 2007 were evaluated for overall survival. Results: Multiple malignancies were present in 34 of 73 patients (47%). Overall 1-, 3-and 5-year survival rates after surgery were 79%, 34%, and 30%, respectively. Presence of symptoms, multiple cancers and level of preoperative tumor marker did not influence post-resection survival. As for tumor characteristics, tumor size, histological tumor differentiation, retroperitoneal invasion, status of residual tumor and UICC staging represented significant prognostic indicators by univariate analysis. Gemcitabine, when administered as an adjuvant settings, strongly worked for improving post-resection outcome (5-year survival rate ¼ 51%). Factors shown to have independent prognostic significance on multivariate analysis were tumor size (,3 vs. 3 cm), status of residual tumor (R0 vs. R1, 2), and postoperative administration of gemcitabine. Conclusions: Appropriate patient selection and accurate surgical technique with postoperative adjuvant therapy could benefit survival of patients with carcinoma of the pancreas body and tail.
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Pancreatic cancer (invasive ductal adenocarcinoma of the pancreas) is the fifth leading cause of cancer death in Japan (1) , and is among the most lethal neoplasms, with almost equal annual death toll and incidence (2) . The pancreas is anatomically segmented into head, body and tail, and invasive carcinoma may arise from any part. Left-sided carcinoma of the pancreas has been reported as more lethal than those arising from the head (3), and some authors have even doubted the effectiveness of resection in treating left-sided carcinoma of the pancreas (4, 5) . In the latest decade, however, several reports have shown the effectiveness of extended resection for such tumors with 5-year survival rates of 14 -19% and long-term survivors and factors for such favorable outcomes have been reported and analyzed (6 -8) .
Meanwhile, gemcitabine has been introduced as a drug to improve overall survival of the patients with advanced pancreatic cancer (9) . And such a newly coming drug was also reported effective for improving the postoperative recurrence-free survival (10, 11) . The present study reviews our recent experiences with resected ductal adenocarcinoma arising in the body and tail of the pancreas, evaluating the clinicopathological characteristics, post-resection survival and factors influencing outcomes after surgery.
PATIENTS AND METHODS

DEMOGRAPHICS, OPERATIVE FACTORS AND TUMOR CHARACTERISTICS
Our policy to select the patients for resection of pancreas cancer is locally resectable neither with gross para-aortic lymph node metastasis nor with distant metastasis in the preoperative diagnostics. Between January 1994 and June 2007, a total of 426 patients underwent surgery for pancreatic tumors at Cancer Institute Hospital, Tokyo, Japan. Among these, 290 patients (68%) had invasive ductal adenocarcinoma, 43 intraductal papillary mucinous neoplasms, 18 mucinous cystic tumors, 12 serous cystadenomas, 3 acinar cell carcinomas, 29 endocrine cell tumors, 9 metastatic tumors and 22 other tumors. Of 290 patients with pancreatic adenocarcinoma, 200 patients (69%) had tumors originating from the head and 90 patients (31%) had tumors of the body or tail. Of the 90 patients with body or tail adenocarcinoma, 4 had gastrointestinal bypass operations and 4 underwent probe laparotomy. After excluding 3 patients with distant metastases (liver, 1 patient; peritoneum, 2 patients) and 6 with invasive adenocarcinoma derived from intraductal papillary mucinous neoplasm, 73 patients remained for further analyses.
The 73 patients included 44 men (60%) and 29 women (40%) with a mean age of 68.0 + 9.2 years (median, 69 years). Various initial symptoms were present in 23 of the 73 patients (32%) on diagnosis of the malignancy, including: abdominal pain (n ¼ 13), back pain (n ¼ 5), nausea (n ¼ 4) and diarrhea (n ¼ 1). Among 50 asymptomatic patients, 3 showed elevated serum amylase levels and 4 had onset or aggravation of diabetes mellitus. Multiple malignancies were present in 34 of the 73 patients (47%). Synchronous multiple malignancies were seen in 6 patients, comprising esophageal, gastric, gallbladder and colon cancer, hepatocellular carcinoma, and malignant lymphoma (n ¼ 1 each). Metachronous multiple malignancies were seen in 28 patients, including: breast cancer (n ¼ 5), prostate cancer (n ¼ 6), gastric cancer (n ¼ 4), uterine cancer (n ¼ 2), esophageal cancer (n ¼ 1), hepatocellular carcinoma (n ¼ 1), colon cancer (n ¼ 4), lung cancer (n ¼ 2) and malignant lymphoma of the stomach (n ¼ 1). The period between pancreatic cancer and other primary cancers ranged from 25.6 years before occurrence of pancreatic carcinoma to 2 years after. One patient had undergone previous treatment for breast cancer, gastric cancer and uterine cancer and another had received treatment for hepatocellular carcinoma and colon cancer. Malignant lymphoma was the only tumor that developed after surgery of pancreatic cancer. All multiple cancers, except for malignant lymphoma and hepatocellular carcinoma, had been surgically resected ( Table 1 ). All pancreatic tumors were solitary and the majority of them arose from the body of the pancreas. Thirty-six tumors (49%) exceeded 3 cm in diameter, with a mean maximum diameter of 3.3 cm. Operative procedures included 66 distal pancreatectomies with splenectomy. Appleby's operation was applied for three patients who had tumors invading to the celiac trunk. For two tumors originating from the body and extending to the level of the gastroduodenal artery, Whipple procedure was performed. As for procedures in detail, distal pancreatectomy was performed in a retrograde manner until 2000, while antegrade distal pancreatectomy was performed for 54 patients from 2001 onwards, involving division of the splenic artery and vein before dissecting the pancreatic body and tail from the retroperitoneum (12) . The peripancreatic lymph nodes were routinely removed according to the operative procedure. At the start of resection, the precaval and intercavoaortic nodes between the level of the left renal vein and the inferior mesenteric artery were dissected after Kocherization. These nodes were just picked and examined by frozen section, when the patients were 76 years old or above.
Intraoperative blood loss was ,1000 ml in 57 patients, and 11 patients (15%) received blood transfusion during surgery. Combined resection and reconstruction of the portal vein was performed in four patients. Among 73 patients, 11 underwent combined resection of other organs due to direct invasion of the tumor, involving the colon in 5 patients, stomach in 5 and left kidney in 1.
Histologically, 36 patients (49%) had well differentiated tubular adenocarcinoma, while histology showed poor differentiation in 4 patients. Among 61 patients for whom status of portal vein invasion was recorded, 22 (36%) showed positive invasion of the portal vein system by the tumor.
Microscopic invasion to retroperitoneal tissues, including the extrapancreatic nerve plexus, was seen in 50 patients (66%). Among 72 patients in whom status of lymph node metastasis was described, 36 (50%) had positive lymph nodes and 18 (25%) had solitary node metastases. Metastasis to para-aortic lymph nodes was seen in nine patients. Microscopic residual tumors were identified on the posterior dissecting surface in 12 patients. Meanwhile 6 patients had R2 resection: 3 at the posterior dissected surface and 5 at the pancreatic cut-stump (2 patients had both at the posterior dissected surface and at the pancreatic stump). According to UICC classification, stages III and IV accounted for 22 patients (30%). In this study, when tumor was found invading to the nerve plexus around the superior mesenteric artery, such tumor was assigned to T4. The 10 stage-4 diseases comprised 9 with para-aortic lymph node metastasis and 1 with the other distant lymph node metastasis. In our department, chemotherapy for invasive pancreatic cancer has been performed using gemcitabine since May 2002. The reasons for using or refraining from gemcitabine varied. Among 18 patients undergoing surgery before May 2002, 16 had no chemotherapy and the remaining 1 had chemotherapy by gemcitabine after recurrence. From April 2002 and March 2005, we participated in the multicenter randomized controlled trial of postoperative adjuvant therapy using gemcitabine. During this period, the patients were treated with this drug during 3 months after surgery, according to the allocation. Among 55 patients after May 2002, the agent was used in an adjuvant setting for 25 patients, while 10 received gemcitabine for recurrent disease. The remaining 20 patients (11 without recurrence and 9 with recurrence) were not treated using gemcitabine. Follow-up information was obtained through direct contact with patients, by investigating the family register and by reviewing hospital charts.
STATISTICS
Both uni-and multivariate methods were used to determine the prognostic significance of various factors in pancreas cancer patients. The primary outcome variable analysed was survival. All continuous data are presented as mean + standard error of the mean. Differences in proportions of categorical variables were evaluated using Pearson's x 2 . Survival curves were generated using Kaplan -Meier methods and were compared using the log-rank test. Patients alive as of June 2008 were censored at the time of follow-up. Multivariate Cox regression analysis was used to identify factors independently associated with survival. Values of P , 0.05 were considered statistically significant.
RESULTS
There was neither 90-day nor in-hospital mortality after surgery. Overall 1-, 3-, and 5-year survival rates 532 Surgery for adenocarcinoma of body and tail of pancreas after surgery were 79, 34 and 30%, respectively. All deaths after discharge were due to tumor recurrence, except for 1 patient who died from acute exacerbation of hepatitis B immediately after chemotherapy for gastric malignant lymphoma with swelling of mediastinal lymph nodes, which was found 2 years after surgery for pancreatic cancer.
UNIVARIATE ANALYSIS
Presence of symptoms, multiple cancers and level of preoperative tumor marker did not influence post-resection survival. Combined resection of other organs due to direct invasion of the tumor or to secure adequate surgical margins were not significant predictors after surgery. Neither increased intraoperative blood loss ,1000 ml nor red blood cell transfusions showed significant prognostic impact on post-resection survival.
As for tumor characteristics, tumor size, histological tumor differentiation, retroperitoneal invasion (including extrapancreatic nerve plexus), status of residual tumor and UICC staging represented prognostic significance. Status of lymph node metastases had no significant effect on patient survival after surgery. Positive para-aortic lymph nodes in nine patients did not influence postoperative outcome. As for postoperative chemotherapy, the patients with postoperative adjuvant use of gemcitabine fared very good to achieve 5-year survival rate of 51%. Contrarily, the outcome of patients who underwent gemcitabine chemotherapy for recurrent tumors was significantly worse than those with adjuvant gemcitabine (P ¼ 0.04) and was comparable to those without chemotherapy (P ¼ 0.54). As a whole, use of gemcitabine significantly improved the post-resection outcome of the patients with body and tail pancreas cancer (Fig. 1) .
MULTIVARIATE ANALYSIS
Possible prognostic factors were selected from univariate analyses and from a review of the literature for further multivariate analyses. When integrated, all data were dichotomized from the results of univariate analyses as follows: multiple primary tumors (absent vs. present), histological differentiation (well vs. others), residual tumor (R0 vs. R1 or R2), number of positive lymph nodes (0 vs. 1) and postoperative use of gemcitabine (not performed vs. performed). The factors of age, sex, operative procedure and UICC staging were not included for multivariate analysis. Factors displaying independent prognostic significance were: (i) tumor size (,3 vs. 3 cm); (ii) residual tumor; and (iii) postoperative use of gemcitabine.
Recurrences were found in 45 (62%) patients: in the liver in 9, liver and other site in 6, lung (only or with other sites) in 4, peritoneum in 6, lymph node in 5, pancreas bed in 4 and remnant pancreas in 4. In seven patients, tumor marker suggested recurrence without evidence of imaging diagnostics.
DISCUSSION
Pancreatic ductal adenocarcinoma remains the fifth leading cause of cancer deaths in Japan (1) and has traditionally displayed a 5-year survival rate ,10% after curative resection. Resectability rate for body and tail lesions is reportedly less than that for head, neck or uncinate lesions, as proximal lesions often cause obstructive jaundice and present earlier, while the disease is still localized to the pancreas, whereas distal lesions tend to have vague, non-specific symptoms and often go undiagnosed until a relatively advanced stage. Recently, however, improvements in pancreatic resection and perioperative adjuvant treatment have combined to produce therapeutic success for such ominous tumors. Several groups have reported markedly improved 5-year survival rates approaching 20% (6 -8,13) for patients undergoing curative resection. Furthermore, a study reported an outstanding 5-year survival rate of 42% after surgery for locally advanced pancreas body and tail cancer without additional treatment (14) . As for long-term prognosis after resection, relatively large series from specialized centers have shown more than 10 long-term survivors after resection (7, 8) , although only three 5-year survivors had been reported for pancreatic body and tail lesions before 1996 (6) .
The present study showed the 5-year survival rate of 30% and included seven patients who survived longer than 5 years. According to an analysis of prognostic factors, such good outcome might largely be due to postoperative use of gemcitabine. As shown in Table 2 and Fig. 1 , the patients with adjuvant gemcitabine fared very good to have 5-year survival rate of 51%. Twenty patients with recurrence and no gemcitabine treatment did not survive longer than 3 years with median survival time of 0.73 year, while 11 patients with gemcitabine for recurrent disease showed two 3-year survivors with median survival time of 1.8 years. The Jpn J Clin Oncol 2010;40 (6) 533 survival of the patients without gemcitabine (5-year survival rate ¼ 23%, median survival time ¼ 1.4 years) is comparable to other reported series (7, 8) . As pancreatic ductal adenocarcinoma is principally a generalized disease even in resected patients, use of adjuvant therapy is the most promising way to improve outcomes after surgery. Several studies have reported fluorouracil-based chemotherapy as effective for pancreatic carcinoma in the adjuvant setting (15, 16) , although two Japanese studies could not confirm any benefit from fluorouracil-based adjuvant chemotherapy (17, 18) . Gemcitabine has been introduced as a drug to improve overall survival and provide definite clinical benefit, such as reducing cancer pain (9) . A German and Japanese group recently reported the definite effectiveness of postoperative adjuvant chemotherapy using gemcitabine to improve recurrence-free survival (10, 11) . Evaluating the effectiveness of this agent in the present study was difficult, since the application of gemcitabine was not randomly controlled in our series. However, the 5-year survival rate of around 50% for patients who received postoperative adjuvant gemcitabine would indicate the possible anti-tumor power of this agent. 534 Surgery for adenocarcinoma of body and tail of pancreas
One of the notable features of the present series was the high ratio (34%) of carcinoma of the body and tail of the pancreas among all resected invasive ductal adenocarcinoma. Almost all western series have included ,10% body and tail tumors among all resected pancreas cancers (6, 19) . Another report from Japan (8) have shown 30% of body and tail carcinomas of all resected tumors and a nationwide survey by the Japanese Pancreas Society reported that cancer of the body and tail of the pancreas comprise 17.5% of all resected tumors (20) . Such a high ratio of body and tail cancer in Japanese series might suggest racial differences in this carcinoma, or alternatively, characteristics of tertiary referral centers specializing in cancer treatment. In the present series, 51 of the 76 patients (67%) had no subjective symptoms on diagnosis of tumor, suggesting relatively early diagnosis by an effective system at outpatient clinics. Another characteristic finding of this series was a low rate [7% (5 of 76)] of poorly differentiated tumor. Such high-grade tumors account for around 40% in western reports (6, 19) . A Japanese nationwide survey reported that poorly differentiated tumor comprised 10.6% of resected cases (20) . Histological differentiation is reportedly one of the tumorrelated factors identified as predictive of post-resection survival (19,21 -23) . Comparable overall survival between this series and others would suggest differences in criteria for pathological diagnosis.
Cancer patients are at high risk of developing a second cancer after the treatment of initial cancers. According to the literature, multiple primary carcinomas in some pancreatic cancer patients might be caused by a genetic predisposition (24) . In the present series, 45% of patients displayed multiple primary tumors other than pancreas cancer. All patients with metachronous multiple cancers were diagnosed as having second pancreatic malignancies during periodic checkups for a previously diagnosed cancer. However, no differences in TNM staging were found between patients with metachronous multiple tumors and those with no or synchronous tumors and post-resection survival time was similar between groups, as already reported (25) . This result suggests aggressive characteristics of the tumor and the difficulty of early diagnosis for pancreatic cancer due to a lack of sensitive screening markers or diagnostic modalities.
R0 resection was an independent factor for post-resection survival in multivariate analysis in the present series (Table 3) . Complete resection is reportedly important in achieving favorable survival after surgery (19, 21, 22, 26) . In the present series, median survival time for R0 resection patients was 2.3 years, comparable to other larger series (6 -8,27 ). The most common site of final positive resection margins is the retropancreatic surface facing the celiac axis or superior mesenteric artery or retroperitoneal tissue (13, 19) . This part cannot be assessed in the early course of resection and further resection to achieve negative margins is usually impossible, particularly when cancer cells have infiltrated into the neural plexus around the celiac axis or superior mesenteric artery. In the present series, 14 of 47 patients with retroperitoneal invasion (30%) displayed cancer-positive dissected margins, while 1 of 24 patient without retroperitoneal invasion (4%) had residual tumor, indicating significant relationship with these factors (P ¼ 0.01). Such a relationship would influence the result of multivariate analysis. Lillemoe et al. (28) and Kuhlmann et al. (29) reported that microscopic incomplete pancreatoduodenectomy gave better survival and palliation to patients with pancreas carcinoma than bypass operation. In the present series, patients with microscopic residual tumor fared similar to those with gross remnant disease after surgery and those of R1 or R2 resection altogether showed median survival of 1.3 years. The latest report of chemotherapy including gemcitabine for locally advanced and/or metastatic pancreatic carcinoma indicated median survival time of 6 -8 months (30 -33) . Thus, our data support the role of palliative distal pancreatectomy, which is simpler and safer compared to the Whipple procedure, in patients with left-sided pancreas cancer.
As for other operative or tumor factors, only tumor size was found to be an independent predictive factor for postresection survival. Tumor size is the factor which has long been reported as a potential prognostic factor after surgery of pancreatic cancer (5, 19, 27, 34) . Intraoperative blood loss and/ or transfusion requirements are frequently reported as predictors of post-resection survival for invasive pancreatic cancers (19, 21, 35) . In the present series, tumor size (,3 vs. 3 cm) had a significant relationship with volume of operative blood loss (,1000 vs. 1000 ml) (P ¼ 0.01 by chi-square test) and tumor stage (P ¼ 0.04 by chi-square test). According to such and above-mentioned interaction, operative blood loss 1000 ml and positive retroperitoneal invasion should not be independent factor in the multivariate context.
The present study revisited and reconfirmed the ominous outcomes of left-sided pancreatic carcinoma. However, we also verified that appropriate patient selection, accurate surgical technique and postoperative adjuvant therapy could provide benefits for the survival of patients with carcinoma of the pancreas body and tail. 
